ATM Inhibition and Metabolic Targeting: Synergistic Vulnerabilities in High Grade Serous Ovarian Cancer

Study Background and Research Question

High grade serous ovarian cancer (HGSOC) remains the most prevalent and lethal subtype of epithelial ovarian cancer (EOC), accounting for the majority of gynecological cancer deaths. Despite advances in debulking surgery and platinum-based chemotherapy, the overall 5-year survival rate for advanced-stage HGSOC is less than 30%. While therapies exploiting deficiencies in the homologous recombination (HR) DNA repair pathway—such as PARP inhibitors—have improved outcomes for a subset of patients, approximately 50% of HGSOC cases are HR-proficient and show poor response to these treatments. This underscores an urgent need for alternative therapeutic strategies targeting HR-proficient tumors.

The serine/threonine kinase Ataxia Telangiectasia Mutated (ATM) is critical for HR-mediated repair of DNA double strand breaks. Notably, ATM is wildtype and its activity is elevated in many HGSOC tumors, with higher nuclear ATM expression correlating with worse survival outcomes. The central research question addressed by the referenced study is whether combining ATM inhibition with agents targeting cellular metabolism could offer a novel therapeutic avenue for HR-proficient HGSOC.

Key Innovation from the Reference Study

The study introduces a paradigm-shifting approach by integrating DNA damage response inhibition with metabolic therapy. Through bioinformatic analyses, the authors observed that ATM expression is inversely correlated with multiple metabolic pathways in HGSOC samples. Building on this, they hypothesized that metabolic vulnerabilities might be unmasked by ATM inhibition. Their key innovation lies in identifying and validating a synergistic interaction between ATM inhibitors and fenofibrate, a clinically approved peroxisome proliferator-activated receptor alpha (PPARα) agonist, in inducing senescence within HGSOC cell lines. This strategy potentially expands the therapeutic landscape for patients whose tumors are resistant to DNA repair-targeted modalities.

Methods and Experimental Design Insights

The authors employed a multifaceted approach combining bioinformatics, pharmacological profiling, and cell-based assays:

• Gene Expression Analysis: ATM status and activity were assessed in HGSOC versus normal fallopian tube tissue, revealing upregulation of ATM in tumors.
• Pathway Correlation: Correlation analysis linked ATM expression with metabolic pathway activity, particularly those governed by PPARα.
• Drug Sensitivity Screening: Data mining of the Dependency Map resource demonstrated that HGSOC cells with low ATM levels are more sensitive to fenofibrate.
• Combination Treatment: Multiple HGSOC cell lines were treated with an ATM kinase inhibitor and fenofibrate, both alone and in combination. Cellular outcomes such as senescence, viability, and proliferation were assessed.
• Synergy Assessment: The interaction between ATM inhibition and fenofibrate was evaluated for synergistic effects using standard drug interaction models.

Core Findings and Why They Matter

The study presents several important discoveries with direct implications for ovarian cancer research and therapy:

• ATM Upregulation and Prognosis: ATM is wildtype and overactive in HGSOC, and higher nuclear ATM correlates with poorer patient survival, suggesting ATM as a relevant therapeutic target.
• Metabolic Pathway Interplay: There is a negative correlation between ATM expression and metabolic pathway activity, especially those modulated by PPARα.
• Synergistic Induction of Senescence: Combined treatment with an ATM inhibitor and fenofibrate robustly induces cellular senescence in HGSOC cells, whereas either treatment alone is less effective. This synergy points to a novel method of halting tumor proliferation in HR-proficient settings.
• Therapeutic Implications: The findings suggest that metabolic reprogramming, an emerging hallmark of cancer, can be exploited in tandem with DNA damage response inhibition. This approach could address a major gap for HR-proficient HGSOC patients who do not benefit from PARP inhibitors or other DNA repair-targeted therapies.

These results provide a compelling rationale for further preclinical and clinical evaluation of ATM kinase inhibitors in combination with metabolic modulators like fenofibrate, especially in the context of platinum-resistant or HR-proficient ovarian cancers. Notably, similar concepts have been explored in glioma research, where ATM inhibition also unmasks metabolic and migratory vulnerabilities (internal article).

Comparison with Existing Internal Articles

Several recent studies have expanded on the mechanistic and translational aspects of ATM inhibition:

• ATM Inhibition and Metabolic Therapy Synergy in Ovarian Cancer—This internal review provides additional context on how ATM inhibition, when paired with PPARα agonists, induces senescence in ovarian cancer models, reinforcing the findings of the reference paper and highlighting the specificity of this approach for HR-proficient disease.
• ATM Inhibition Promotes Macropinocytosis and Metabolic Adaptation in Cancer—This article elucidates how ATM inhibition drives adaptive metabolic responses such as macropinocytosis, further supporting the rationale for targeting metabolic pathways in combination with DNA repair inhibitors.
• KU-60019: Selective ATM Inhibitor for Advanced Glioma Research—This study on glioma models demonstrates that selective ATM inhibition represses cell migration and invasion, paralleling the metabolic and prosurvival signaling vulnerabilities observed in ovarian cancer cells. These cross-tumor findings suggest that ATM inhibitors such as KU-60019 can be leveraged to expose and exploit cancer-specific weaknesses.

Together, these resources highlight a growing consensus that ATM inhibition not only disrupts DNA repair but also rewires cancer cell metabolism, opening up new combinatorial therapy opportunities.

Limitations and Transferability

While the synergy between ATM inhibition and fenofibrate is robust in cell culture models, several limitations must be considered:

• Preclinical Maturity: The current findings are based on in vitro HGSOC cell lines. The transferability of this strategy to in vivo models and ultimately to clinical settings remains to be established.
• ATM Inhibitor Choice: The study does not address differences between various ATM kinase inhibitors regarding specificity, off-target effects, or pharmacokinetics.
• Metabolic Complexity: Cellular metabolic pathways are highly context-dependent; thus, the observed synergy may not generalize across all tumor types or metabolic states.
• Mechanistic Depth: Further mechanistic studies are needed to clarify how ATM inhibition sensitizes cells to PPARα-driven metabolic stress and whether other metabolic agents could achieve similar synergy.

Despite these caveats, the approach sets the stage for translational studies aiming to expand treatment options for HR-proficient, therapy-resistant ovarian cancers.

Protocol Parameters

• ATM kinase inhibitor administration: In referenced cell line experiments, ATM inhibitors are typically applied at concentrations ranging from 1–10 μM, depending on the specific inhibitor and the cellular context (reference study).
• Fenofibrate treatment: Fenofibrate is administered at concentrations empirically determined to activate PPARα signaling and induce metabolic stress, generally in the low micromolar range.
• Combination regimen: Cells are exposed to both ATM inhibitor and fenofibrate for 48–72 hours, with senescence and viability assessed post-treatment.
• Control conditions: Include DMSO-treated controls and single-agent treatments to evaluate synergistic versus additive effects.
• Workflow suggestion: For extrapolation to other cancer models, titrate inhibitor concentrations and validate synergy using viability and senescence markers relevant to the tumor type under study.

Research Support Resources

For researchers aiming to replicate or extend these findings in ovarian or other cancer models, highly selective ATM kinase inhibitors are essential. KU-60019 (SKU A8336) from APExBIO is a potent ATM kinase inhibitor with documented activity in cell-based and in vivo models. Its high selectivity and solubility parameters facilitate its use in studying DNA damage response inhibition, radiosensitization, and metabolic pathway interplay in cancer research. For established protocols, KU-60019 is typically used at 3 μM for in vitro experiments and 10 μM for in vivo studies involving intratumoral delivery. As always, investigators should consult the product dossier and optimize parameters for their specific experimental system.